Synchronous primary endometrial and ovarian cancers: A multicenter review of 63 cases

Simple item page
dc.contributor.authorSolmaz U.
dc.contributor.authorKaratasli V.
dc.contributor.authorMat E.
dc.contributor.authorDereli L.
dc.contributor.authorHasdemir P.S.
dc.contributor.authorEkin A.
dc.contributor.authorGezer C.
dc.contributor.authorSayhan S.
dc.contributor.authorSanci M.
dc.contributor.authorGuvenal T.
dc.date.accessioned2024-07-22T08:11:39Z
dc.date.available2024-07-22T08:11:39Z
dc.date.issued2016
dc.description.abstractAims: To investigate clinicopathologic characteristics, therapeutic methods, and prognostic factors in women with synchronous primary endometrial and ovarian cancers (SEOCs). Methods: A retrospective review of 2 cancer registry databases in Turkey was conducted to identify patients diagnosed with SEOCs between January 1995 and December 2012. Patients with recurrent, metastatic, and metachronously occurring tumors were excluded. Multivariate logistic regression models were used to identify prognostic predictors for progression-free survival (PFS) and overall survival (OS). Results: The analysis included 63 women with SEOCs. Seventy-six percent of the patients had stage I endometrial cancer, and 60% of the patients had stage I ovarian cancer. Thirty-seven patients (58.7%) had endometrioid/ endometrioid histology. Optimal cytoreduction was obtained in 47 (74.6%) patients. Recurrence developed in 17 patients (27%). Multivariate analysis confirmed lymphovascular space invasion (LVSI) as an independent poor prognostic factor for OS (odds ratio [OR] 3.1, p = 0.045), whereas early-stage disease and optimal cytoreduction were found to be independent good prognostic factors for both PFS (OR 12.85, p<0.001 and OR 4.58, p = 0.004, respectively) and OS (OR 7.31, p = 0.002 and OR 2.95, p = 0.028, respectively). The 3- and 5-year OS rates were 74% and 69%, respectively. Conclusions: Our study demonstrated that optimal cytoreduction, early-stage disease, and LVSI are the most significant factors affecting survival in women with SEOC.
dc.identifier.DOI-ID10.5301/tj.5000378
dc.identifier.issn03008916
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15738
dc.language.isoEnglish
dc.publisherWichtig Publishing Srl
dc.subjectBiomarkers, Tumor
dc.subjectCombined Modality Therapy
dc.subjectComorbidity
dc.subjectEndometrial Neoplasms
dc.subjectFemale
dc.subjectHumans
dc.subjectNeoplasm Grading
dc.subjectNeoplasm Staging
dc.subjectNeoplasms, Multiple Primary
dc.subjectOvarian Neoplasms
dc.subjectRegistries
dc.subjectRetrospective Studies
dc.subjectSurvival Analysis
dc.subjectTreatment Outcome
dc.subjectTurkey
dc.subjectcarboplatin
dc.subjectcisplatin
dc.subjectdocetaxel
dc.subjectdoxorubicin
dc.subjectpaclitaxel
dc.subjecttumor marker
dc.subjectabdominal hysterectomy
dc.subjectadult
dc.subjectappendectomy
dc.subjectArticle
dc.subjectcancer prognosis
dc.subjectcancer radiotherapy
dc.subjectcancer recurrence
dc.subjectcancer registry
dc.subjectcancer survival
dc.subjectcytoreductive surgery
dc.subjectendometrium cancer
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectlymph node dissection
dc.subjectlymph vessel
dc.subjectmajor clinical study
dc.subjectovary cancer
dc.subjectoverall survival
dc.subjectpredictor variable
dc.subjectprogression free survival
dc.subjectretrospective study
dc.subjectsalpingooophorectomy
dc.subjectsynchronous primary endometrial and ovarian cancer
dc.subjecttumor invasion
dc.subjectTurkey (republic)
dc.subjectcancer grading
dc.subjectcancer staging
dc.subjectclinical trial
dc.subjectcomorbidity
dc.subjectEndometrial Neoplasms
dc.subjectfemale
dc.subjectmeta analysis
dc.subjectmortality
dc.subjectmulticenter study
dc.subjectmultimodality cancer therapy
dc.subjectNeoplasms, Multiple Primary
dc.subjectOvarian Neoplasms
dc.subjectregister
dc.subjectsurvival analysis
dc.subjecttreatment outcome
dc.subjectTurkey
dc.titleSynchronous primary endometrial and ovarian cancers: A multicenter review of 63 cases
dc.typeArticle

Files

Collections

Scopus Koleksiyonu